CLOPICARD AP 75

Description

Clopicard AP 75 is a dual antiplatelet therapy (DAPT) medicine manufactured by Cipla Ltd. It combines Clopidogrel (75mg) and Aspirin (75mg), both of which work together to prevent the formation of harmful blood clots in arteries and veins. This reduces the risk of heart attack, stroke, and other cardiovascular complications.

How It Works:

• Clopidogrel (75mg): A P2Y12 receptor inhibitor that prevents platelets from sticking together and forming clots.

• Aspirin (75mg): A salicylate that inhibits thromboxane A2, reducing platelet aggregation and clot formation.
  Together, they offer stronger protection than either medicine alone.

Uses of Clopicard AP 75:

• Prevention of recurrent heart attacks and strokes

• Protection after angioplasty or coronary stent placement

• Management of acute coronary syndrome (ACS)

• Long-term therapy for patients with peripheral arterial disease (PAD) and other circulation problems

Key Benefits:

• Dual protection against dangerous clot formation

• Reduces the chance of future heart-related events

• Improves blood flow in narrowed arteries

• Essential therapy after heart surgery or stent procedure

Dosage & Administration:

• Typically taken once daily, with or without food, as directed by a doctor

• Must be taken regularly at the same time every day

• Do not discontinue the medicine suddenly without medical consultation, as this may increase the risk of clot formation

Possible Side Effects:

• Increased risk of bleeding (nosebleeds, gum bleeding, easy bruising)

• Gastric irritation, acidity, or stomach upset due to aspirin

• Rarely: black stools, vomiting blood, allergic skin reactions

• Very rarely: severe bleeding complications

Precautions:

• Use with caution in patients with bleeding disorders, peptic ulcers, liver or kidney problems

• Avoid alcohol, as it increases the risk of stomach bleeding

• Inform your doctor about other medications, especially blood thinners (warfarin, heparin), NSAIDs, or other antiplatelets

• Not recommended in pregnancy, breastfeeding, or in children unless advised by a doctor

Conclusion:
Clopicard AP 75, a combination of Clopidogrel (75mg) + Aspirin (75mg) by Cipla Ltd, is a powerful antiplatelet therapy widely prescribed for patients at risk of heart attack, stroke, and clot-related complications. It provides dual protection, making it a cornerstone treatment for patients with heart disease and those who have undergone stent placement.